Oppenheimer & Co. Inc. Sells 27,823 Shares of Moderna, Inc. (NASDAQ:MRNA)

Oppenheimer & Co. Inc. reduced its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 73.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,964 shares of the company's stock after selling 27,823 shares during the quarter. Oppenheimer & Co. Inc.'s holdings in Moderna were worth $414,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB raised its holdings in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after buying an additional 587 shares during the last quarter. Compass Planning Associates Inc bought a new stake in Moderna during the 4th quarter valued at $37,000. Venturi Wealth Management LLC increased its position in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after purchasing an additional 664 shares during the period. MassMutual Private Wealth & Trust FSB increased its position in Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after purchasing an additional 389 shares during the period. Finally, Blue Trust Inc. increased its position in Moderna by 53.1% during the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock valued at $47,000 after purchasing an additional 388 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Remove Ads

Moderna Stock Up 3.8 %

MRNA traded up $1.31 during midday trading on Friday, hitting $35.61. 17,290,858 shares of the company traded hands, compared to its average volume of 12,693,394. The firm has a market capitalization of $13.74 billion, a PE ratio of -3.84 and a beta of 1.86. The company's 50-day moving average is $36.60 and its 200 day moving average is $49.03. Moderna, Inc. has a 52 week low of $29.25 and a 52 week high of $170.47.

Analysts Set New Price Targets

A number of research analysts have issued reports on MRNA shares. JPMorgan Chase & Co. set a $45.00 price objective on shares of Moderna in a research report on Friday, February 14th. HSBC raised shares of Moderna from a "hold" rating to a "buy" rating and set a $58.00 price objective on the stock in a research report on Monday, November 18th. Royal Bank of Canada reissued a "sector perform" rating and set a $40.00 price objective on shares of Moderna in a research report on Tuesday, February 18th. Barclays downgraded shares of Moderna from an "overweight" rating to an "equal weight" rating and reduced their price objective for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Finally, UBS Group reduced their price objective on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a research report on Wednesday, February 19th. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $60.63.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.